BLICKENSTAFF KIM D 4

What Happened

• Kim D. Blickenstaff, a director of Nuvation Bio (NUVB), was granted/received 123,397 derivative shares on May 21, 2026. The transaction is reported as an award/grant (Form 4 code A) with an acquisition price of $0.00, for a reported value of $0 on the filing. This is a compensation-style grant, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-21; Form 4 filed: 2026-05-26 (appears to be filed after the 2-business-day reporting window).
• Security: 123,397 derivative shares (award/grant); reported price: $0.00.
• Shares owned after the transaction: Not specified in the provided filing details.
• Vesting: Footnote states 100% of the shares subject to the award vest on the earlier of (i) the one‑year anniversary of the grant date (May 21, 2026) or (ii) the next shareholder annual meeting, subject to continuous service through the applicable vesting date.
• Transaction code: A = Award/Grant (derivative); no immediate sale or cashless exercise reported.

Context

• This award is typical of director compensation and does not reflect an open-market purchase or sale; such grants are often meant to align director interests with shareholders. Because the filing reports a $0 acquisition price and lists vesting conditions, the award may be restricted stock units or another time-vesting derivative instrument.
• The filing date (May 26) is later than the transaction date (May 21). Insiders are generally required to file Form 4 within two business days of the transaction; a late filing can be a compliance issue and is noted here for investors.